Company: Amgen Inc.
Ticker: AMGN
Form: 10-K
Filed: 2026-02-13
Fiscal Period: {"fp": "FY", "fy": 2025}

Question: What was Amgen Inc.'s operating cash flow margin in fiscal year 2025?
Question Type: derived_ratio

Concept: NetCashProvidedByUsedInOperatingActivities
RevenueFromContractWithCustomerExcludingAssessedTax
Answer (Numeric): 27.1
Answer (Display): 27.10%
Unit: percent

Evidence:
[{"chunk_id": "281", "equivalent_chunk_ids": ["281"], "section": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "supports": ["numerator", "denominator"], "text": "Years ended December 31, 2025, 2024 and 2023\n(In millions)\nCash flows from operating activities:\nNet income\n7,711\n4,090\n6,717\nNoncash adjustments to reconcile net income to net cash provided by operating activities:\nDepreciation, amortization and other\n5,167\n5,592\n4,071\nImpairment of intangible assets\n1,200\nStock-based compensation expense\nDeferred income taxes\n1,228\n1,273\n(Gains) losses on equity securities\n2,064\n1,565\nOther items, net\nChanges in operating assets and liabilities, net of acquisitions:\nTrade receivables, net\n2,676\n1,015\nInventories\n2,532\nOther assets\n1,267\nAccounts payable\nAccrued income taxes, net\n2,068\n1,011\n1,031\nLong-term tax liabilities\nAccrued liabilities\nAccrued sales incentives and allowance\n2,065\n1,194\nOther liabilities\nNet cash provided by operating activities\n9,958\n11,490\n8,471\nCash flows from investing activities:\nCash paid for acquisitions, net of cash acquired\n26,989\nProceeds from sales of marketable securities\n1,123\nProceeds from maturities of marketable securities\nPurchases of property, plant and equipment\n1,858\n1,096\n1,112\nOther\nNet cash used in investing activities\n1,943\n1,046\n26,204\nCash flows from financing activities:\nNet proceeds from issuance of debt\n27,777\nExtinguishment of debt\nRepayment of debt\n5,000\n3,600\n1,454\nRepurchases of common stock\nDividends paid\n5,124\n4,832\n4,556\nOther\nNet cash (used in) provided by financing activities\n10,859\n9,415\n21,048\n(Decrease) increase in cash and cash equivalents\n2,844\n1,029\n3,315\nCash and cash equivalents at beginning of year\n11,973\n10,944\n7,629\nCash and cash equivalents at end of year\n9,129\n11,973\n10,944\nSee accompanying notes.\nF-8\nAMGEN INC."}]

Derivation: {"denominator": "revenue", "denominator_value": 36751.0, "format": "percentage", "numerator": "operating_cash_flow", "numerator_value": 9958.0, "op": "divide"}